Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trialSalvatore Siena, Takayuki Yoshino, Maria Di Bartolomeo et al.|The Lancet Oncology|2021Cited by 411
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studiesYoshiaki Nakamura, Takayuki Yoshino, Masahiro Goto et al.|Nature Medicine|2020Cited by 366
Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancerHisato Kawakami, Kazuhiko Nakagawa, Junko Tanizaki et al.|Investigational New Drugs|2017Cited by 170
Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancerTakayuki Yoshino, Maria Di Bartolomeo, Kanwal Raghav et al.|Nature Communications|2023Cited by 159
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trialKanwal Raghav, Takayuki Yoshino, Salvatore Siena et al.|The Lancet Oncology|2024Cited by 124